Addiction journal
Addiction journal
Xylazine, heroin and drug markets with Caroline Copeland
Xylazine, heroin and drug markets with Caroline Copeland
Xylazine, heroin and drug markets with Caroline Copeland
Tuesday 9th April 2024
Dr. Caroline Copeland exposes the hidden dangers of xylazine in the UK drug market and its severe health impacts. Tune in for vital insights.
21 minutes
Informative
Empowering
Hopeful
Transformative
Educational
About this podcast
Author:
Addiction journal
Overview:
Categories:
Navigating Alcohol Dependency
Understanding Addiction & Recovery
Navigating Intimate Relationships
Family Recovery from Addiction
Nutritional Pathways to Recovery
Links:
Visit site
Episodes:
87 (View all)
Do you want to link to this podcast?
Get the buttons here!The Hidden Dangers of Xylazine: Dr. Caroline Copeland's Insights on the UK Drug Scene
Episode Overview
- Dr. Copeland's expertise in pharmacology and toxicology
- Xylazine's emergence in the UK drug market beyond heroin supplies
- Implications of xylazine on public health and drug policies
- Recommendations for addressing synthetic drug threats
- Importance of monitoring drug trends and promoting research findings
It's absolutely horrible... Zyazine a rampant drug in the US in combination with fentanyl to the point where it was declared in April last year in the US as an emerging threat to the United States.
Ever wondered what new threats are lurking in the illicit drug market? In this episode of Addiction Audio, Dr. Caroline Copeland joins Ben Scher to unpack her groundbreaking research on xylazine, a substance making alarming inroads into the UK drug scene. Dr.
Copeland, a senior lecturer at King’s College London and director of the National Programme on Substance Use Mortality, paints a stark picture of xylazine's dangers, from its entry into the US market to its unexpected presence in UK vapes and heroin supplies. She doesn't hold back on the grim details: xylazine can cause blood vessels to contract, leading to tissue death, severe sores, and even amputations if infections set in.
This episode isn't just a cautionary tale; it's a call to action for public health practitioners and policymakers. Dr. Copeland emphasizes the urgent need for informed decisions and harm reduction strategies to combat this evolving threat. If you're curious about the complexities of drug trends and the critical role of research in shaping effective policies, this conversation is a must-listen.